BMS Files For Japan Approval Of Daclatasvir/Asunaprevir Hepatitis C Drug
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb filed an application in Japan for the approval of NS5A replication inhibitor daclatasvir, currently under development, and the NS3 protease inhibitor asunaprevir for combination use in genotype 1b Hepatitis C virus therapy.